Patent: 9,700,485

Summary for Patent: 9,700,485

Title:	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
Abstract:	The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, FORTEO.RTM. (recombinant human teriparatide), DULAGLUTIDE.RTM. (LY2189265), recombinant insulin glargine, RAMUCIRUMAB.RTM. (IMC-1121B), SOLANEZUMAB.RTM. (LY2062430), IXEKIZUMAB.RTM. (LY2439821), TABALUMAB.RTM. (LY2127399), NECITUMUMAB.RTM. (IMC-11F8), or CIXUTUMUMAB.RTM. (IMC-A12).
Inventor(s):	Weeks; Wendell P. (Corning, NY), Schaut; Robert Anthony (Painted Post, NY), DeMartino; Steven Edward (Painted Post, NY), Peanasky; John Stephen (Big Flats, NY)
Assignee:	Corning Incorporated (Corning, NY)
Application Number:	14/259,259
Patent Claims:	see list of patent claims

Details for Patent 9,700,485

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	04/20/2000		2039-02-26
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	04/25/2007		2039-02-26
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/18/2014		2039-02-26
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/04/2020		2039-02-26
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	04/21/2014		2039-02-26
Eli Lilly And Company	PORTRAZZA	necitumumab	Injection	125547	11/24/2015		2039-02-26
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	12/16/2015		2039-02-26